SCHEMBL724156

SCHEMBL724156

Cc1c(C(=O)C2CCCCC2)sc2cccnc12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 1/20 0.45
ALDH1A1 P00352 2/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 3/20 0.40
TP53 P04637 2/20 0.40
LMNA P02545 1/20 0.39
SLC2A1 P11166 1/20 0.39
GAA P10253 1/20 0.39
ESR1 P03372 1/20 0.37
RORC P51449 2/20 0.36
DHODH Q02127 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
HPGD P15428 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL718690 0.79 IKBKB (0.45) LIMK1ALDH1A1MAPTTP53GAA
SCHEMBL717434 0.76 PRNP (0.51) LIMK1ALDH1A1MAPTLMNAGAA
SCHEMBL5776212 0.76 LIMK1 (0.69) LIMK1MAPTLMNAGAACYP2C19
SCHEMBL720933 0.74 CYP2C9 (0.46) ALDH1A1MAPTLMNAGAAESR1
SCHEMBL719608 0.74 KDM4E (0.44) ALDH1A1HTTMAPTTP53LMNA
SCHEMBL1811307 0.73 LIMK1 (0.50) LIMK1ALDH1A1HTTMAPTTP53
SCHEMBL9541081 0.72 LIMK1 (0.43) LIMK1ALDH1A1HTTMAPTTP53
SCHEMBL716644 0.71 LMNA (0.49) LIMK1ALDH1A1MAPTLMNAGAA
SCHEMBL719825 0.71 CYP2C19 (0.47) ALDH1A1HTTMAPTTP53GAA
SCHEMBL20711523 0.70 KDM4E (0.43) ALDH1A1LMNAGAADHODHCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP LIMK1 4140/4885ALDH1A1 504/4885HTT 1337/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP LIMK1 4140/4885ALDH1A1 504/4885HTT 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.